

February 3, 2020

The General Manager Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 500770 National Stock Exchange of India Ltd. Exchange Plaza Bandra-Kurla Complex Bandra (E) Mumbai 400 051 Symbol: TATACHEM

Dear Sir,

Sub: Submission of Analysts/Investors Presentation

Ref.: Letter dated January 24, 2020 informing about Analysts/Investors Presentation

Further to our referred letter, please find enclosed a presentation to be made to analysts/investors on the results for the third quarter and nine months ended December 31, 2019 for the analysts/investors call to be held today i.e. Monday, February 3, 2020.

The presentation is being submitted in compliance with Regulation 30(6) read with Schedule III Part A Para A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

A copy of the presentation is also uploaded on the Company's website www.tatachemicals.com.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Tata Chemicals Limited

Rajiv Chandan

General Counsel & Company Secretary

Encl.: a/a





Analyst / Investors Communication on Financial results for period ended December 2019 Date: 3<sup>rd</sup> February 2020



## **Safe Harbour Statement**

"This Presentation, except for the historical information, may contain statements, including the words or phrases such as 'expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should' and similar expressions or variations of these expressions or negatives of these terms indicating future performance or results, financial or otherwise of Tata Chemicals Limited, its direct and indirect subsidiaries and its associates. Actual results might differ substantially or materially from those expressed or implied. Important factors that could make a difference to the Company's operations include, among others, economic conditions affecting demand / supply, price conditions in the domestic and overseas markets in which the Company operates, changes in Government policies and regulations, tax laws, and other statutes and incidental factors. You are urged to view all statements contained herein with caution. Tata Chemicals Limited does not undertake any obligation to update or revise forward look statements, whether as a result of new information, future events or otherwise"



## **Business Overview**




3<sup>rd</sup> largest Soda Ash producer globally | 5,000+ employees across 4 continents

| 160 million households consume Tata Salt each month

ZZ



# **Our Journey till date**





## **Business Updates**

## **Basic Chemistry Products**

- Mithapur expansion plan is scheduled as planned.
- Acquired balance 25% stake in TCSAP from The Andover Group for USD 195 million.

### **Specialty Products**

#### **Nutritional Science**

- Mambattu plant started trials. Reached quality benchmark
- Products are under global approval process, normally take long gestation period for product approval

#### **Material Science**

- Commercial production of non rubber & rubber grade Silica proceeding as planned
- Continue to focus on customers approvals (tyre & non tyre OEM ) through customer engagement and their specific requirements.

#### **Agro Science**

- To add distributors with higher variable incentives linked targets and Increase focus on specialty product
- Continue investing in capacity expansion and registration in International markets with focus on high margin exports, especially to South East Asian countries
- Rallis and Metahelix merger effective 1<sup>st</sup> Feb 2020, with effect from April 2019

#### **Energy Science**

- Received support from Gujarat government to set up greenfield manufacturing facility. Land has been allotted in Dholera, Gujarat
- In advanced stage of discussions with potential technology partners

Planned Schedule (MT)									
Products	Soda Ash	Bicarb	Salt	Caustic	Cement				
Existing	0.8 MMT	0.1MMT	1.0 MMT	9КМТ	0.5 MMT				
Dec19									
Mar20			140k						
Jun20	20k								
Sept20				9k					
Dec20					300k				
Mar21			20k		3000				
Jun21	25k								
Sept21		35k							
Dec21									
Mar22	155k		240k						
Planned	1.0 MMT	0.14 MMT	1.4 MMT	18 KMT	0.8 MMT				





**Q3 Dec 2019 Financial Updates** 



# **Key Highlights**

Consumer Products Business considered as Discontinued Operations

Acquired balance 25% stake in TCSAP from The Andover Group for USD 195 million

## **Revenue from Operations (Continuing Operation)**

Standalone for the quarter ended was at ₹ 756 Cr (vs PY ₹ 757 Cr)

Consolidated for the period ended was at ₹ 2,620 Cr (vs PY ₹ 2,570 Cr)

## **Net Profit for the Company (Continuing & Discontinued Operations)**

Standalone for the quarter was at ₹ 211 Cr (vs PY ₹ 128 Cr),

Standalone for the period ended was at ₹ 288 Cr (vs PY ₹ 266 Cr)


## **Borrowing and Cash Position**

On Standalone basis, company is gross debt free company with cash of ₹ 2,412 Cr

In Consolidated books net borrowings (including Lease Liabilities) stood at ₹ 3,726 Cr, Cash and Cash equivalent ₹ 3,362 Cr




## **Financial Updates: For the Quarter December 2019**



Note: \* PAT includes Continuing & Discontinued Operations, after Share in JV & associates & before NCI



## **Financial Updates: For the Period ended December 2019**



Note: \*PAT includes Continuing & Discontinued Operations, after Share in JV & associates & before NCI





# **Segment Revenues and Results**

Rs Cr	Conso	lidated	Standalone		
KS CI	Q3 Dec 18	Q3 Dec 19	Q3 Dec 18	Q3 Dec 19	
Basic Chemistry Products	2,142	2,007	746	726	
Specialty Products	429	604	12	21	
Less: Inter Segment Revenue	(3)	(3)	-	-	
	2,568	2,608	758	747	
Unallocated Revenue	2	13	(1)	9	
Total Segment Revenue	2,570	2,620	757	756	
Basic Chemistry Products	283	328	183	213	
Specialty Products	9	40	(6)	(8)	
Segment Results	292	367	177	204	
Unallocated Expenses / (Income)	95	75	20	4	
Less: Finance Costs	(44)	(4)	25	1	
Profit after exceptional items, before share of profit of joint ventures and tax	242	297	132	199	




# Segment Revenues and Results (with Discontinued Operations)

		Consoli	dated	Standalone			
	Rs Cr	YTD Dec18	YTD Dec19	Q3 Dec18	Q3 Dec19		
Continuing	Segment Revenue	2,570	2,620	757	756		
Operations	Segment Results	292	367	177	204		
Discontinued	Segment Revenue	471	531	471	531		
Operation	Segment Results	57	82	57	82		
					777777		



## **Borrowings Position as on December 2019**







## **Segment: Basic Chemistry Products**

- TCL India: Revenue at ₹726 Cr (down by 3%, vs PY ₹746 Cr), margins on the Soda ash continues to improve over PY, leading to Segment results at ₹213 Cr (up by 16%, PY ₹183 Cr).
- TCNA: Revenue at ₹872 Cr (down by 2%, vs PY ₹889 Cr), primarily due to adverse market pricing during the quarter. EBITDA was at ₹183 Cr (up by 7% vs PY ₹171 Cr).
- TCE Group: Revenue at ₹348 Cr (down by 7%, vs PY ₹371 Cr), due to lower sales & trading volumes. EBITDA was at ₹46 Cr (up by 229% vs PY ₹14 Cr) on account of better sales mix between own make vs trading and lower gas price.
- TCML: Revenue at ₹79 Cr (down by 45%, vs PY ₹144 Cr), due to lower sales volumes, despite better sales realization. EBITDA was at ₹(9) Cr (down by 131% vs PY ₹29 Cr) on the back of higher fixed costs.








## **Segment: Specialty Products**

- Nutritional Solutions and Other Specialty products: Revenues at ₹ 21 Cr vs PY
   ₹ 12 Cr, mainly on account of higher sales volumes. Margins where muted on account of higher marketing fixed cost.
- Commercial production of non rubber & rubber grade Silica proceeding as planned
- Rallis India Limited: Revenue at ₹ 534 Cr, (up by 28%, vs PY ₹ 417 Cr), increase is primarily on account of volume growth in domestic crop protection, crop nutrition and International business.
- EBITDA margin improved on account of improved sales realization, despite some price correction in some of our molecules, both in domestic and the international market.








# **Segment: Consumer Products Business (Discontinued operations)**

- **Salt Business:** Tata Salt continues to maintain its leadership position in the branded salt segment with market share more than 25% in the overall edible salt market and ~65% market share in branded Salt market in India.
- Salt portfolio continues to go strong in the market with higher sales volumes (up 3% at 301 kts. Vs. PY 293 kts.). Margins improved on account of lower marketing cost.
- Pulses and Spices: Pulses and Spices portfolio continues to perform well with revenue growth of ~22% (vs PY), despite of strong competition from regional brands and unorganized market.
- **New products:** Tata Dx detergent, TATA Sampann Mixes, Poha and other products continue to get good traction in the market.





## **Financial updates: Operating Entities**

## Statement of Profit and Loss (Continuing Operations) for the quarter ended Dec 2019

Units	TCL I	ndia	U	S	U	K	Afr	ica	Ral	llis	Consoli	dated*
₹Cr	PY	CY	PY	CY	PY	CY	PY	CY	PY	CY	PY	CY
Revenue	757	756	889	872	371	348	144	79	417	534	2,570	2,620
EBITDA	165	195	171	183	14	46	29	(9)	28	56	412	473
PBT	132	199	80	79	(35)	8	19	(20)	20	48	242	297
PAT	89	150	35	40	(35)	8	19	(20)	14	36	180	172

## Statement of Profit and Loss (Continuing Operations) for the period ended Dec 2019


Units	TCL Ir	ndia	US		U	K	Afr	ica	Ral	llis	Consoli	dated*
₹Cr	PY	CY	PY	CY	PY	CY	PY	CY	PY	CY	PY	CY
Revenue	2,260	2,175	2,512	2,603	1,068	991	365	342	1,644	1,906	7,775	7,968
EBITDA	506	574	473	557	78	106	27	39	234	269	1,334	1,545
PBT	716	719	221	256	(23)	1	(2)	5	215	240	942	1,033
PAT	522	587	102	133	(23)	1	(2)	5	154	185	590	625


<sup>\*</sup> Consolidated financials is after adjusting SPV & Consolidation adjustments


<sup>•</sup> PBT is after exceptional items & Share in JV and PAT (after NCI) for Equity Shareholders





## **Volumes : Major Products**

















<sup>\*</sup> Edible Salt




## **Additional Information**









# Accelerating focussed growth

For any question/queries please contact

🎍 John Mulhall		+91 22 6665 8282
🕹 Sameer Kulkarni	sakulkarni@tatachemicals.com	+91 22 6665 7942
🕹 Gavin Desa	gavin@cdr-india.com	+91 22 6645 1237
& Suraj Digawalekar	suraj@cdr-india.com	+91 22 6645 1235

Registered Office: Bombay House, 24 Homi Mody Street, Fort, Mumbai, Maharashtra 400 001 India.

Tel: (022) 6665 8282 Fax: (022) 6665 8143 / 44